Dexcom Wins CMS Coverage for Continuous Glucose Monitor

Dexcom announced that the Centers for Medicare & Medicaid Services agreed to cover its G6 continuous glucose monitoring system for Medicare beneficiaries.

The system features a redesigned applicator that inserts a small sensor below the user’s skin to continuously measures glucose levels for up to 10 days and transmit the data to a display device.

The G6 won FDA approval in March and a CE Mark in April. The company expects to start shipping the system to Medicare customers in early 2019.